NAS10029,644+0.67%S&P7,651+0.17%GOLD$4,417−0.18%BTC$81,133−0.12%VIX14.81−4.08%live tape · as of 23:00 UTC · 20 Sep
The Screen · Healthcare · Healthcare Plans
Centene Corporation
CNC · a US exchange · USD · Market cap $31.6B · 61,000 employees
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States.
Positioning political selling, disclosed 2026-08-10
Options no verdict drawn today, left as found
Ethical passes the values gate
Price64.06 USD
Fair value65.05
Ethical score70.9/100
RatingFAIR VALUE
Our investment reviews on this name
2026-08-25Read Accumulation65.02-1.5% to today
2026-07-02Read Markup62.33+2.8% to today ✓
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Centene Corporation holds its Accumulation at $64.06. Consolidating, no directional conviction, held for 47 days.
As held on the ledger · 2026-09-09
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 47 days
Price at the screen
$64.06
Valuation
N/A trailing · 12.06 forward price to earnings
Values screen
PASS· score 70.9
Beta
1.11
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
23.66%
Below 33%
Interest-bearing debt is just 23.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
22.20%
Below 33%
Cash held in interest-bearing accounts and securities is 22.2% of assets, under the one-third limit.
Pass
Receivables
46.90%
Below 49%
Money owed to the company is 46.9% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads FAIR VALUE: it trades at roughly a 2% discount to our $65.05 fair value, weak competitive moat, 4.60% revenue growth.
Fair value range in USD, drawn from the 2026-09-09 screen. The gold marker is the market price at the same screen. A 1.6% margin of safety to the base estimate.
Third-party analyst targets: 18 covering, consensus Buy. The average target sits +10% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-09 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Medicaid Safety Net Trades Past Fair Value
Picture a firm paid to cover the families regular insurers skip. Centene sits in that spot, running Medicaid and Medicare plans across four segments. Shares at 66 dollars sit 10 percent above our 60 dollar fair value line, so the opportunity rating stays at fair value.
Revenue edges up 5 percent yet the business posts a negative 4 percent profit margin and negative 26 percent return on equity. A weak moat and forward price to earnings of 14.8 times do not change the fact that returns remain poor. The ethical screen clears, yet that alone does not lift the case.
Analysts lean buy with a 68 dollar median target, but negative returns and thin growth leave plenty of room for disappointment if reimbursement rates tighten. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
CNC trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 46% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (17 analysts) rates it buy, with a mean price target of $58.
2026-07-25Markup$66.44+6.6%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 46% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (17 analysts) rates it buy, with a mean price target of $58.
2026-07-18Markup$62.33+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 46% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (17 analysts) rates it buy, with a mean price target of $58.
2026-07-03Markup$62.33+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (71). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$62.33Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (71). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
